Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone for multiple sclerosis.

F Martinelli Boneschi1, M Rovaris, R Capra

  • 1Scientific Institute Ospedale San Raffaele, Nerological Department, Via Olgettina, 48, Milano, Italy 20132. filippo.martinelli@hsr.it

The Cochrane Database of Systematic Reviews
|October 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients.

Molecular neurobiology·2021
Same author

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2018
Same author

Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.

European journal of neurology·2018
Same author

Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.

Journal of neurology·2018
Same author

Functional Characterization of the Left Ventrolateral Premotor Cortex in Humans: A Direct Electrophysiological Approach.

Cerebral cortex (New York, N.Y. : 1991)·2016
Same author

Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Mitoxantrone (MX) moderately reduces disease progression and relapses in multiple sclerosis (MS) patients within two years. Long-term safety concerns, including cardiotoxicity and leukemia risk, warrant further investigation before widespread use.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Mitoxantrone (MX) demonstrates moderate efficacy in managing disease activity in multiple sclerosis (MS).
  • Assessing MX's effectiveness and safety across different MS subtypes is crucial for treatment guidance.

Purpose of the Study:

  • To evaluate the efficacy and safety of Mitoxantrone (MX) in patients with relapsing-remitting MS (RRMS), progressive relapsing MS (PRMS), and secondary progressive MS (SPMS).

Main Methods:

  • Comprehensive literature search of multiple databases (Cochrane, MEDLINE, EMBASE) up to April 2005.
  • Inclusion criteria specified double-blinded, placebo-controlled, randomized trials, regardless of concurrent therapies.
  • Data extraction and quality assessment performed independently by three reviewers.

Related Experiment Videos

Main Results:

  • Four trials with 270 participants indicated MX reduced disability progression at 2 years (OR 0.3, p=0.05).
  • Significant reductions observed in annualized relapse rates and active MRI lesions.
  • Adverse events were more frequent in the MX group; however, trial heterogeneity limits definitive conclusions.

Conclusions:

  • Mitoxantrone (MX) shows moderate short-term efficacy (2 years) in reducing disease progression and relapse frequency in RR, PR, and SP MS.
  • No major short-term cardiotoxicity or neoplastic effects were reported in the included trials.
  • Long-term safety, particularly cardiotoxicity and leukemia risk, requires further study; MX use is recommended for worsening RR and SP MS with evidence of disability progression.